The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial

Condition:   Hepatocellular Carcinoma Interventions:   Drug: Xiang Sha Liu Jun Zi Decoction dry powder;   Drug: XSLJZ Placebo Sponsor:   China Medical University Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials